ImmuniCell® Clinical Trial in the United Kingdom
First written in FY2016-Q3. 1 of 3 entries say "Advanced", first in FY2017. Latest entry: FY2019.
No other company in this theme has enough history to compare yet.
- FY2019DroppedAnnual report
「TC BioPharm, to which we licensed our processing technology, obtained approval from the UK Medicines and Healthcare products Regulatory Agency and began a clinical trial of ImmuniCell® (autologous χδ T cells) in December 2015. Safety was confirmed in Stage 1, and the trial proceeded to Stage 2 to select the target tumors. However, because patient enrollment was taking longer than expected, we determined that completing the trial would be difficult and decided to discontinue it.」
The ImmuniCell® Stage 2 trial was discontinued after the company determined that completion would be difficult because patient enrollment was taking too long. - FY2017AdvancedAnnual report
「TC BioPharm, to which we have licensed our processing technology, obtained approval from the UK Medicines and Healthcare products Regulatory Agency and began the ImmuniCell® clinical trial in December 2015. Stage 1 has been completed and, following confirmation of safety, the trial proceeded to Stage 2.」
The UK ImmuniCell® trial completed Stage 1 and proceeded to Stage 2 after safety was confirmed. - FY2016-Q3First statedAnnual report
「In December 2015, UK-based TC BioPharm Ltd., established with the Company’s investment to develop and sell cell therapy products in Europe, began a clinical trial in the United Kingdom for ImmuniCell®, a cell therapy product, using cell processing technology and know-how licensed by the Company and the clinical experience accumulated by the Company.」
The UK subsidiary began the ImmuniCell® clinical trial based on licensed technology and know-how and accumulated clinical experience.